As ALS progresses, annual healthcare costs for U.S. patients increase from an average of $31,000 to over $120,000, a Biogen ...
HEALEY ALS, a platform trial testing multiple potential treatments for amyotrophic lateral sclerosis, is amending its master ...
The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time ...
Neurosense is finalizing the protocol of a Phase 3 study of PrimeC for ALS, and plans to submit the protocol for FDA approval ...
Columnist Kristin Neva must take on more caregiver duties as her husband's ALS progresses, which means she must shift her ...
The Centers for Medicare and Medicaid Services is directing all Medicare Advantage plans to cover Qalsody for treating ...
Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback